The GvHD Hub was pleased to speak to Andrew Gennery, Newcastle University and Great North Children’s Hospital, Newcastle upon Tyne, UK, and Chair of the UK Photopheresis Society, about the future directions of extracorporeal photopheresis (ECP) for the treatment of graft-versus-host disease (GvHD).

View on the GvHD Hub here: https://gvhdhub.com/medical-information/future-perspectives-of-ecp-for-gvhd-treatment

Gennery begins by providing a background to using ECP in pediatric patients, including the potential complications involved and how to mitigate these. He then discusses the process of ECP, including treatment scheduling, and its efficacy in different types of GvHD.

Gennery goes on to speak about how the treatment landscape for GvHD has changed in the last 5 years, how it might change in the future, and where ECP fits in as an immunomodulatory agent. In the future, ECP may be combined with the newer immunosuppressive agents that are approved, or in development, for the treatment of GvHD to deliver positive outcomes for patients.

This independent educational activity was supported by Mallinckrodt Pharmaceuticals. All content was developed independently by the faculty. The funder was allowed no influence on the content of this activity.

Hosted on Acast. See acast.com/privacy for more information.